Urination Therapeutic Drug Brachyantheraoside A2 Affects the Therapeutic Window of Zidovudine

作者：Ge, Bo; Liao, Ran; Li, Peng-Cheng; Song, Ya-Hui; Huang, Jie-Fu; Gao, Li; Zhou, Li; Zhang, Tian-Yu^*

来源：Latin American Journal of Pharmacy, 2015, 34(2): 413-415.

• Brachyantheraoside A2
• Drug-drug interaction
• Zidovudine (AZT)

Yemuosides, the compounds isolated from Stauntonia chinensis, exhibited multiple biochemical and pharmacological activities. Yemuosides exhibit anti-inflammation activity, and may be used in urinary diseases. The deglycosylated product of yemuosides is brachyantheraoside A2. The present study aims to investigate the inhibition of brachyantheraoside A2 towards the glucuronidation metabolism of zidovudine (AZT), which is an important drug clinically used to treat HIV/AIDS infection; 100 uM of brachyantheraoside A2 inhibited the 80% activity of AZT glucuronidation. Furthermore, the inhibition kinetic type was determined using Lineweaver-Burk plot, and noncompetitive inhibition type was detected. The second plot using the slopes from the lines in Lineweaver-Burk plot versus the concentration of brachyantheraoside A2 was used to calculate the inhibition kinetic parameter (Ki) to be 39.1 uM. All these data indicated the drug-drug interaction between brachyantheraoside A2 and AZT.

• 出版日期2015
• 单位桂林医学院